Print |
  • Text A A
  • PDxProstateSubPageGraphic.png

     

    ERG and PTEN:
    Addressing an Unmet Need in Prognosis for Gleason Score 6 and 71

    ERG-PTEN-300dpi.png

    References

    1. National Comprehensive Cancer Network.  NCCN Guidelines for Prostate Cancer (Version 4.2013). http://www.nccn.org, Accessed November, 12 2013.

    2. Bismar TA, Yoshimoto M, Vollmer RT, et al.  PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.  BJU International.  2011;107:477-85.

    This test was developed by and its performance characteristics determined by PersonalizeDx. It has not been cleared or approved by the U.S. Food and Drug Administration. PersonalizeDx is a CLIA-accredited laboratory CLIA ID #05D2001811. This test is used for clinical purposes. The clinical validity of the test has been established based upon review of relevant literature. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity testing.